HRTX Projected Dividend Yield
Heron Therapeutics Inc ( NASDAQ : HRTX )Heron Therapeutics is a commercial-stage biotechnology company focused on developing treatments for acute care and oncology patients. Co.'s oncology care product portfolio includes SUSTOL, which is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide combination chemotherapy regimens. Co.'s acute care product portfolio includes: ZYNRELEF, which is indicated in adults for soft tissue or periarticular instillation; and APONVIE (HTX-019), which is indicated for the prevention of postoperative nausea and vomiting in adults. 20 YEAR PERFORMANCE RESULTS |
HRTX Dividend History Detail HRTX Dividend News HRTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |